Novartis’ innovative biologic omalizumab pre-filled auto-injection pen has been approved in the country.
March 20, 2026
Source: drugdu
29
On March 19, 2026, Novartis announced that its innovative biologic, Zorla® ( omalizumab), a pre-filled auto-injector pen, has been approved by the National Medical Products Administration for the treatment of adults and adolescents (12 years and older) with chronic spontaneous urticaria (CSU) and patients diagnosed with IgE (immunoglobulin E)-mediated asthma who still have symptoms after treatment with H1 antihistamines. (This product is indicated for adults and adolescents (12 years and older) with moderate to severe persistent allergic asthma whose symptoms are not effectively controlled after treatment with inhaled corticosteroids and long-acting inhaled β2 - adrenergic receptor agonists.)
According to reports, Zorula has been on the global market for over 20 years, with multiple dosage forms and indications, and is widely used in more than 90 countries and regions, including China.
https://www.vbdata.cn/1519067858
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Baiyang Pharmaceuticals makes a strategic investment in Sihe Gene, further strengthening its ASO (App Store Optimization) small nucleic acid innovation strategy. March 20, 2026
- Multi-resistance pipeline outbreak March 20, 2026
- Qilu Pharmaceutical’s first ophthalmic preparation, cyclosporine ophthalmic emulsion, was exported to the United States. March 20, 2026
- Novartis’ secukinumab, used to treat hidradenitis suppurativa, has been approved for a new indication March 20, 2026
- The world’s first prescription for ribevirtadalab (Huayounuo®) has been officially issued March 20, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
